Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

NCT03519854 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromuscular Blockade

Interventions

DRUG: Placebo
DRUG: Sugammadex
DRUG: Esmeron®

Sponsor

Merck Sharp & Dohme LLC